Evidence map›Paper›PMID 34106373›Full record

ArticleClinical and experimental nephrology2021

Pleiotropic effect of erythropoiesis-stimulating agents on circulating endothelial progenitor cells in dialysis patients.

Takashi Naito, Manabe Shun, Hideki Nishimura, Tomoki Gibo, Mai Tosaka, Moe Kawashima, Akitoshi Ando, Tetsuya Ogawa, Tsutomu Sanaka, Kosaku Nitta

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Takashi NaitoDepartment of Medicine, Tokyo Rosai Hospital, Tokyo, Japan. takashi020304@yahoo.co.jp.ORCID http://orcid.org/0000-0003-4911-815X
Manabe ShunDepartment of Medicine, Tokyo Rosai Hospital, Tokyo, Japan.
Hideki NishimuraDepartment of Medicine, Medical Center East, Tokyo Women's Medical University, Tokyo, Japan.
Tomoki GiboDepartment of Medicine, Tokyo Rosai Hospital, Tokyo, Japan.
Mai TosakaDepartment of Medicine, Tokyo Rosai Hospital, Tokyo, Japan.
Moe KawashimaDepartment of Medicine, Tokyo Rosai Hospital, Tokyo, Japan.
Akitoshi AndoDepartment of Medicine, Tokyo Rosai Hospital, Tokyo, Japan.
Tetsuya OgawaDepartment of Medicine, Medical Center East, Tokyo Women's Medical University, Tokyo, Japan.
Tsutomu SanakaLife Style Disease Center, Edogawa Hospital, Tokyo, Japan.
Kosaku NittaDepartment of Medicine, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan.
Tokyo Women's Medical University · JPTokyo Women's Medical University Adachi Medical Center · JPEdogawa Hospital · JPTokyo Rosai Hospital · JP

Funding

Kidney Foundation, Japan JFKB 17-7
6 · The paper itself

Abstract

backgroundRecent studies have suggested that erythropoiesis-stimulating agents (ESAs) may accelerate not only angiogenesis but also vasculogenesis, beyond erythropoiesis.

methodsWe conducted a 12-week prospective study in 51 dialysis patients; 13 were treated with recombinant human erythropoietin (EPO, 5290.4 ± 586.9 IU/week), 16 with darbepoetin (DA, 42.9 ± 4.3 µg/week), 12 with epoetin β pegol (CERA, 40.5 ± 4.1 µg/week) and 10 with no ESAs. Vascular mediators comprising endothelial progenitor cells (EPCs), vascular endothelial growth factor (VEGF), matrix metalloproteinase-2 (MMP-2), and high-sensitivity C-reactive protein (hs-CRP) were measured at 0 and 12 weeks. EPCs were measured by flow cytometry as CD45

resultsThe EPC count increased significantly to a greater extent in the EPO group than in the other three group, and increased significantly from 0 to 12 weeks in a EPO dose-dependent manner. In both the DA and CERA groups, the EPC count did not change at 12 weeks. Serum levels of VEGF, MMP-2 and hs-CRP were not affected by ESA treatment in all groups. In the CERA group, serum ferritin decreased significantly compared to the no-ESA group and correlated with CERA dose, although use of iron was permitted if required during the prospective study period of 12 weeks.

conclusionsWhen patients on dialysis were treated with clinical doses of various ESAs, only EPO induced a significant increase of circulating EPCs from bone marrow, whereas, DA and CERA had no effect.

Indexed as

AgedAnemiaCell CountC-Reactive ProteinDarbepoetin alfaEndothelial Progenitor CellsErythropoietinFemaleFerritinsHematinicsHumansKidney Failure, ChronicMaleMatrix Metalloproteinase 2Middle AgedNeovascularization, Physiologiccontinuous erythropoietin receptor activatorC-Reactive ProteinDarbepoetin alfaErythropoietinFerritinsHematinicsMatrix Metalloproteinase 2MMP2 protein, humanPolyethylene GlycolsRecombinant ProteinsVascular Endothelial Growth Factor AVEGFA protein, humanDarbepoetinEndothelial progenitor cellsEpoetin β pegolErythropoiesis-stimulating agentsRecombinant human erythropoietin

Identifiers

PMID34106373
OpenAlexW3166793106

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.